CBO0 Stock Chart & Stats
€1.28
-€0.01(-0.80%)
At close: 4:00 PM EDT
€1.28
-€0.01(-0.80%)
Day’s Range― - ―
52-Week Range€1.08 - €4.44
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€6.61M
Enterprise Value€10.29
Total Cash (Recent Filing)€6.86M
Total Debt (Recent Filing)€7.85M
Price to Earnings (P/E)―
Beta0.59
Next Earnings
Nov 16, 2026EPS Estimate
-0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.53
Shares Outstanding5,611,403
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.15
Price to Sales (P/S)0.00
P/FCF Ratio-0.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€13.78Price Target Upside976.73% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-2.16
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyThe reported overall-survival benefit provides meaningful clinical validation for IMUNON-001 and supports the potential for differentiated therapeutic value. If confirmed in later-stage analysis, this efficacy signal could strengthen regulatory prospects, partnering interest, and long-term commercial positioning.
Phase III Enrollment ExecutionEnrollment materially ahead of assumptions demonstrates operational execution and supports faster progression toward important clinical milestones. Sustained site productivity can improve development efficiency, help maintain investigator engagement, and increase confidence that the company can advance its lead program on schedule.
Favorable Safety ProfileA favorable safety profile can improve the therapy’s practical usability and reduce risks that tolerability issues disrupt development or limit adoption. Consistency across multiple clinical settings also strengthens the product’s differentiation and may support continued enrollment and regulatory review.
Bears Say
Limited Cash Runway And Financing DependenceThe company remains dependent on additional financing to complete its pivotal development program, creating a durable constraint on execution. Capital raising may increase dilution, financing costs, or strategic limitations, while an inability to secure funds could delay trials and weaken negotiating leverage.
Minimal Revenue And Persistent LossesIMUNON currently lacks a meaningful revenue base to offset research and development spending, so continued operations depend on external capital. Persistent losses and negative cash generation reduce financial resilience, limit strategic flexibility, and leave profitability dependent on successful future clinical commercialization.
Debt And Preferred-stock Financing BurdenAlthough the restructuring reduces part of the debt principal, the new preferred securities impose an ongoing 8% return, potential redemption premiums, and heightened default economics. These obligations can consume future cash, constrain capital allocation, and increase financial pressure while the pipeline remains uncommercialized.
Imunon News
CBO0 FAQ
What was Imunon’s price range in the past 12 months?
Imunon lowest stock price was €1.08 and its highest was €4.44 in the past 12 months.
What is Imunon’s market cap?
Imunon’s market cap is €6.61M.
When is Imunon’s upcoming earnings report date?
Imunon’s upcoming earnings report date is Nov 16, 2026 which is in 46 days.
How were Imunon’s earnings last quarter?
Imunon released its earnings results on Aug 11, 2026. The company reported -€0.477 earnings per share for the quarter, beating the consensus estimate of -€0.766 by €0.29.
Is Imunon overvalued?
According to Wall Street analysts Imunon’s price is currently Undervalued.
Does Imunon pay dividends?
Imunon does not currently pay dividends.
What is Imunon’s EPS estimate?
Imunon’s EPS estimate is -0.49.
How many shares outstanding does Imunon have?
Imunon has 5,611,403 shares outstanding.
What happened to Imunon’s price movement after its last earnings report?
Imunon reported an EPS of -€0.477 in its last earnings report, beating expectations of -€0.766. Following the earnings report the stock price went up 1.55%.
Which hedge fund is a major shareholder of Imunon?
Currently, no hedge funds are holding shares in DE:CBO0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Imunon
Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. The company's pipeline features GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a proprietary heat-activated liposomal formulation of doxorubicin, currently in development for various cancer indications. Additionally, Imunon possesses two feasibility-stage platform technologies aimed at creating nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Established in 1982 and based in Lawrenceville, New Jersey, the firm was known as Celsion Corporation before rebranding to Imunon, Inc. in September 2022.
CBO0 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong clinical and translational momentum (robust Phase II OS gains, encouraging MRD signals, favorable safety) and operational execution (enrollment outperforming assumptions, cost discipline, recent financing), balanced against near-term financing needs and uncertainties tied to small MRD sample size and event-driven timing of Phase III interims. Overall the positives (clinical validation, enrollment traction, operational control) outweigh the negatives (short runway, need for additional capital, statistical limitations of MRD).View all DE:CBO0 earnings summariesCBO0 Stock 12 Month Forecast
Average Price Target
€13.78
▲(976.73% Upside)